BioNTech and DualityBio report positive data for trastuzumab pamirtecan Hospital Management 11:30 Mon, 13 Apr Pharma Biotech
BioNTech to Report First Quarter 2026 Financial Results and Corporate Update on May 5, 2026 BioNTech (Press Release) 7d
BioNTech and DualityBio report positive data for trastuzumab pamirtecan Hospital Management 11:30 Mon, 13 Apr
BioNTech and DualityBio’s Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer BioNTech (Press Release) 12:10 Sat, 11 Apr
